About: Transcription factor NF-kappaB inhibitors as single therapeutics agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Transcription factor NF-kappaB inhibitors as single therapeutics agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Nuclear factor-kappaB (NF-kappaB) upregulates the transcription of proteins that promote cell survival, stimulate growth, induce angiogenesis and reduce susceptibility to apoptosis. NF-kappaB signaling pathway is constitutively activated in myelodysplastic syndrome (MDS), acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, lymphomas and in multiple myeloma (MM). The overexpression of NF-kappaB and its anti-apoptotic cytoprotective effect suggest that it might be a useful therapeutic target for the treatment of hematologic malignancies. Several drugs effective for the treatment of MM, including proteasome inhibitors, thalidomide, lenalidomide and arsenic trioxide, block NF-kappaB activation. New agents with NF-kappaB inhibitory ativity enhance the anti-MM effects of conventional chemotherapeutic agents and reduce different side-effects. These agents are also studied in the therapy of other hematologic malignancies. Nuclear factor-kappaB (NF-kappaB) upregulates the transcription of proteins that promote cell survival, stimulate growth, induce angiogenesis and reduce susceptibility to apoptosis. NF-kappaB signaling pathway is constitutively activated in myelodysplastic syndrome (MDS), acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, lymphomas and in multiple myeloma (MM). The overexpression of NF-kappaB and its anti-apoptotic cytoprotective effect suggest that it might be a useful therapeutic target for the treatment of hematologic malignancies. Several drugs effective for the treatment of MM, including proteasome inhibitors, thalidomide, lenalidomide and arsenic trioxide, block NF-kappaB activation. New agents with NF-kappaB inhibitory ativity enhance the anti-MM effects of conventional chemotherapeutic agents and reduce different side-effects. These agents are also studied in the therapy of other hematologic malignancies. (en)
Title	Transcription factor NF-kappaB inhibitors as single therapeutics agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies Transcription factor NF-kappaB inhibitors as single therapeutics agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies (en)
skos:prefLabel	Transcription factor NF-kappaB inhibitors as single therapeutics agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies Transcription factor NF-kappaB inhibitors as single therapeutics agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies (en)
skos:notation	RIV/00023736:_____/10:00008797!RIV12-MZ0-00023736
http://linked.open...avai/riv/aktivita	P Z
http://linked.open...avai/riv/aktivity	P(LC06044), Z(MZ0UHKT2005)
http://linked.open...iv/cisloPeriodika	3
http://linked.open...vai/riv/dodaniDat	2012
http://linked.open...aciTvurceVysledku	Fuchs, Ota
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Ústav hematologie a krevní transfúze
http://linked.open...dnocenehoVysledku	293274
http://linked.open...ai/riv/idVysledku	RIV/00023736:_____/10:00008797
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	hematological malignancies; NF-kappaB; NF-kappaB inhibitors; proteasome inhibitors (en)
http://linked.open.../riv/klicoveSlovo	NF-kappaB inhibitors NF-kappaB hematological malignancies proteasome inhibitors
http://linked.open...odStatuVydavatele	AE - Stát Spojené arabské emiráty
http://linked.open...ontrolniKodProRIV	[BABB4FE9BF12]
http://linked.open...i/riv/nazevZdroje	Current Molecular Pharmacology
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	1 (xsd:int)
http://linked.open...vavai/riv/projekt	Center for Experimental Hematology
http://linked.open...UplatneniVysledku	2010
http://linked.open...v/svazekPeriodika	3
http://linked.open...iv/tvurceVysledku	Fuchs, Ota
http://linked.open...n/vavai/riv/zamer	Význam molekulárně biologických vyšetření pro objasnění patogeneze a pro diagnostiku poruch krvetvorby a využití krvetvorné buňky v léčbě onemocnění krvetvorby a jiných tkání.
issn	1874-4672
number of pages	25 (xsd:int)

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 77 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software